10-K: Personalis Reports 2025 Losses Amid Revenue Decline, Boosts Cash

Personalis, Inc. reported an 18% revenue decrease in 2025, driven by reduced enterprise sales, but strengthened its cash position and secured key Medicare coverage for its cancer diagnostic tests.

Summary

• Total revenue for 2025 decreased by 18% to $69.6 million, down from $84.6 million in 2024.
• The company reported a net loss of $81.3 million for both 2025 and 2024, with an accumulated deficit of $631.3 million as of December 31, 2025.
• Cash, cash equivalents, and short-term investments increased to $240.0 million by the end of 2025, up from $185.0 million in 2024, partly due to $109.0 million in net proceeds from At-The-Market (ATM) sales.
• Clinical diagnostic revenue more than doubled to $2.0 million in 2025 from $0.8 million in 2024, with test volume increasing by nearly 400% to 16,233 tests.
• Medicare coverage was secured for NeXT Personal Dx for post-treatment surveillance of Stage II and III breast cancer (effective October 7, 2025) and Stage I to III non-small cell lung cancer (effective January 9, 2026).
• The partnership with Tempus AI, Inc. was expanded in December 2024 to include biopharma customers and further expanded in July 2025 to market NeXT Personal Dx for colorectal cancer, extending the agreement term through November 25, 2029.
• Revenue from Enterprise sales, primarily Natera, significantly decreased to $5.9 million in 2025 from $25.4 million in 2024, as the commercial relationship with Natera is no longer material.
• Population sequencing revenue increased by 58% to $11.8 million in 2025, driven by increased sample processing for the VA MVP.
• Research and development expenses increased by 3% to $50.3 million in 2025, while selling, general and administrative expenses increased by 16% to $53.6 million.
• The FDA's final rule on the regulation of Laboratory Developed Tests (LDTs) was vacated by a U.S. District Court in March 2025 and officially rescinded in September 2025, reverting LDTs to CLIA framework regulation.
• The company's Amended and Restated Bylaws were updated on February 24, 2026, to modernize stockholder proposal procedures and clarify voting standards.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While significant Medicare coverage and increased clinical test volumes are strong positives for future growth, the substantial revenue decline, ongoing net losses, and the loss of a major customer (Natera) present considerable headwinds and financial instability.

Positives

• Secured Medicare coverage for NeXT Personal Dx for post-treatment surveillance of Stage II and III breast cancer (effective October 7, 2025).
• Received Medicare coverage for NeXT Personal Dx for surveillance of Stage I to III non-small cell lung cancer (effective January 9, 2026).
• Clinical test revenue more than doubled to $2.0 million in 2025, a 166% increase from 2024.
• Clinical test volume increased by nearly 400% to 16,233 tests in 2025.
• Published landmark TRACERx data in 'Cell' journal, highlighting the ultrasensitive MRD approach for NSCLC.
• Published VHIO data in 'Clinical Cancer Research' reinforcing the clinical validity of the NeXT Personal platform across various cancer types.
• Ended 2025 with a strong cash position of $240.0 million in cash, cash equivalents, and short-term investments, including $109.0 million from ATM sales.
• Expanded collaboration with Tempus AI, Inc. to include biopharma customers and market NeXT Personal Dx for colorectal cancer, extending the agreement through November 25, 2029.
• The FDA's final rule on LDT regulation was vacated and rescinded, reducing immediate regulatory burden on the company's diagnostic tests.

Negatives

• Total revenue decreased by 18% to $69.6 million in 2025 compared to $84.6 million in 2024.
• Experienced a significant decrease in Enterprise sales revenue, primarily from Natera, which fell from $25.4 million in 2024 to $5.9 million in 2025, as the commercial relationship is no longer material.
• Continued to incur substantial net losses, with $81.3 million in 2025 and $81.3 million in 2024.
• Customer concentration remains high, with Moderna and VA MVP accounting for 22% and 17% of 2025 revenue, respectively.
• Cost of revenue decreased at a lesser rate than revenue, leading to lower fixed overhead absorption and increased clinical diagnostic test costs relative to reimbursement.
• The company has a history of losses and expects to incur significant losses for the foreseeable future, with an accumulated deficit of $631.3 million.
• Previous workforce reductions in Q1 and Q4 2023 collectively affected nearly 50% of the workforce, indicating past operational challenges.

Risks

• Inability to generate sufficient revenue to achieve or sustain profitability due to ongoing significant losses.
• Failure to increase sales of current testing services or successfully develop and commercialize other services, or gain sufficient market acceptance.
• Substantial customer concentration, particularly with Moderna and the VA MVP, and the loss of a material commercial relationship with Natera.
• Challenges in establishing medical necessity for coverage and adequate reimbursement rates for clinical diagnostic tests.
• Partnering and collaboration agreements, including with Tempus, Myriad, Moderna, and Merck, may not be successful or may terminate.
• Reliance on a limited number of suppliers, or sole suppliers like Illumina, for laboratory instruments and materials, posing supply chain risks.
• Adverse effects from international trade policies, including tariffs, sanctions, and trade barriers.
• Risk of business disruption if the single Fremont facility becomes damaged or inoperable, or if the company is required to vacate it.
• Inability to develop testing services that keep pace with rapid advances in technology, medicine, and science.
• Heightened regulatory scrutiny, delays in clinical development, or delays/inability to achieve regulatory approval, commercialization, or payor coverage for personalized cancer therapies.
• Loss of key executive management team members or inability to hire, retain, or motivate highly skilled personnel.
• Inability to manage future growth effectively, straining organizational, administrative, and operational infrastructure.
• Risks associated with potential acquisitions, joint ventures, or investments in other companies or technologies, including harm to operating results or dilution.
• Tests may be subject to regulatory action if they do not comply with statutory and regulatory requirements enforced by the FDA or equivalent foreign authorities and/or CLIA requirements.
• Compliance with numerous statutes and regulations is expensive and time-consuming, with potential for substantial penalties for non-compliance.
• Information technology systems or data, or those of third-party vendors, may fail or suffer security breaches, leading to adverse consequences.
• Failure or perceived failure to comply with data privacy and security laws and obligations could harm the business.
• Employees may engage in misconduct or other improper activities, leading to significant liability and reputational harm.
• Changes in healthcare policy could increase costs, decrease revenue, and impact sales and reimbursement for tests.
• Litigation or other proceedings or claims of intellectual property infringement, misappropriation, or other violations could require significant time and money and prevent test sales.
• Inability to license rights to use necessary technologies on reasonable terms could prevent commercialization of new services.
• Inability to obtain, maintain, and enforce patent protection for testing services or technologies, allowing competitors to develop similar offerings.
• Inability to protect the confidentiality of trade secrets and know-how, harming business and competitive position.
• Use of open source software could subject proprietary software to general release or litigation.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Inability to raise additional capital on acceptable terms in the future may limit business operations and expansion.
• Volatility or steep decline in the market price of common stock, regardless of operating performance, leading to potential loss of investment.
• Significant fluctuations in quarterly results due to variable sample volumes and other factors.
• Unstable market, economic, and geopolitical conditions, including inflation and interest rate changes, could adversely affect the business.
• Adverse developments affecting the financial services industry could impair access to cash and liquidity.
• Significant control by insiders or holders of greater than five percent of outstanding common stock could influence corporate matters.
• Future sales of shares by existing stockholders could cause the stock price to decline.
• No current intention to pay dividends on common stock, making investment return dependent on stock price appreciation.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution.
• Lack of research or inaccurate/unfavorable research by securities analysts could cause stock price and trading volume to decline.
• Issuance of preferred stock could adversely affect common stockholders.
• Limitations on the ability to use net operating losses to offset future taxable income.
• Delaware law and provisions in the amended and restated certificate of incorporation and bylaws could make a merger, tender offer, or proxy contest difficult.
• Exclusive forum provisions in the amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Requirements of being a public company consume substantial resources, may result in litigation, and divert management's attention.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Failure to maintain effective internal control over financial reporting could adversely affect financial reporting accuracy and timing.

Future Outlook

The company expects to continue incurring significant net losses for the foreseeable future as it scales its business and operations. Future performance depends on the adoption of ultrasensitive MRD testing, continued development of the genomic-based test market, increasing adoption by existing and new biopharma customers, and obtaining further diagnostic test coverage and reimbursement. Capital expenditures are projected to increase to $8-10 million in 2026 and $10-12 million in 2027 and 2028 to expand NeXT Personal Dx capacity. The company anticipates fulfilling the new VA MVP task order during the first three quarters of 2026. There is uncertainty regarding the impact of future healthcare policy changes and the ability to raise additional capital on acceptable terms.

Management Comments

• We are pioneering the ultrasensitive MRD testing market with the belief that an ultrasensitive approach will lead to earlier intervention and the ability to better trust that a negative MRD patient is likely cancer-free.
• Our performance depends on the willingness of pharmaceutical companies, enterprise customers, and oncologists to continue to seek more comprehensive molecular information to develop more efficacious cancer therapies.
• We believe having our tests covered by Medicare is important to and a key catalyst for clinical revenue and market share growth in the MRD testing market.
• We anticipate that our current cash and cash equivalents and short-term investments are sufficient to fund our near-term capital and operating needs for at least the next 12 months.

Industry Context

StockSavvy.ai notes that Personalis operates in the highly competitive and rapidly evolving cancer genomic testing market. The company's focus on ultrasensitive minimal residual disease (MRD) detection aligns with a growing trend in precision oncology for earlier and more precise cancer monitoring. The recent vacating and rescinding of the FDA's LDT rule provides temporary regulatory relief, allowing LDTs to remain primarily under CLIA, which is favorable for companies like Personalis that market their tests as LDTs. However, the industry faces ongoing challenges with reimbursement for novel diagnostic tests and intense competition from larger, well-funded players like Natera, Guardant Health, and Exact Sciences. The company's strategy of building clinical evidence through collaborations with leading cancer centers is crucial for driving adoption and securing reimbursement, a common hurdle for innovative diagnostic services.

Comparison to Industry Standards

• Personalis' NeXT Personal Dx is positioned as an ultrasensitive test for MRD detection, aiming to detect cancer recurrence earlier than other technologies. This differentiates it from competitors like Natera (Signatera) and Guardant Health (Guardant Reveal) by emphasizing ultra-high sensitivity, which could be a key competitive advantage if clinical outcomes consistently demonstrate superior early detection.
• The company's comprehensive tumor profiling test, NeXT Dx, competes with offerings from Foundation Medicine (FoundationOne CDx) and Caris Life Sciences, which also provide extensive genomic insights for therapy selection. Personalis highlights its matched tumor-normal analysis and exome/transcriptome sequencing as differentiators.
• In the population sequencing market, Personalis' WGS services for initiatives like the VA MVP compete with large-scale sequencing providers, including those utilizing Illumina's platforms. The company's stated capacity to sequence and analyze over 350 trillion bases of DNA per week suggests a significant operational scale, comparable to major genomics service providers.
• The company's reliance on Illumina as a sole supplier for sequencers and reagents is a common industry practice but also a significant risk, as seen with other genomics companies dependent on specific platform providers.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2025, the company was not involved in any material legal proceedings.
• Previously filed complaints against Foresight Diagnostics for infringement of certain patents relating to detection of MRD, which were dismissed in June 2024 pursuant to a settlement agreement.
• Two of the company's patents were challenged and subsequently invalidated during inter partes reviews initiated by Foresight.

Related Party Transactions

• Tempus AI, Inc. is a related party due to owning more than 10% of the company's common stock after exercising warrants and purchasing additional shares in August 2024.
• Merck Sharp & Dohme LLC (Merck) is a related party due to owning more than 10% of the company's common stock after purchasing shares in December 2024.
• Revenue from Tempus AI, Inc. related to the Tempus Agreement was $0.5 million for the year ended December 31, 2025, with $0.4 million outstanding as a receivable.
• Market Development Fees of $4.2 million from Tempus were unamortized as of December 31, 2025.
• Sales and marketing expenses related to Tempus were $4.6 million for the year ended December 31, 2025.
• Invoiced $4.9 million to Merck in 2025 for DNA and RNA sequencing analysis and data interpretation services, with $2.0 million outstanding as a receivable as of December 31, 2025.

Stakeholder Impact

• **Shareholders:** Experience dilution from ongoing ATM sales and previous equity offerings. The stock price is subject to volatility due to operating performance, market conditions, and analyst expectations. Continued net losses and customer concentration pose risks to investment value, while Medicare coverage and strategic partnerships offer potential for future growth.
• **Employees:** Subject to internal restructuring activities and workforce reductions (nearly 50% in 2023), which can impact morale and job security. The company emphasizes competitive total rewards, training, and diversity, but competition for skilled personnel remains intense. Stock-based compensation is a significant part of their rewards.
• **Customers (Pharmaceutical/Biopharmaceutical):** Benefit from advanced cancer genomic testing services for clinical trials and drug development. The company's ability to deliver high-quality, timely data is crucial for their success. The expansion of partnerships with companies like Tempus and Merck indicates continued value proposition.
• **Customers (Clinical Diagnostic):** Benefit from new Medicare coverage for NeXT Personal Dx in breast and lung cancer, potentially increasing access to advanced MRD testing. The focus on building clinical evidence aims to drive adoption and improve patient outcomes.
• **Suppliers:** The company's reliance on a limited number of suppliers, particularly Illumina, creates dependency and potential risks if supply is disrupted or pricing changes.
• **Regulatory Bodies:** The company is subject to extensive federal, state, and foreign regulations (CLIA, FDA, HIPAA, anti-kickback laws). Compliance is costly and time-consuming, with potential for significant penalties for violations. The vacating of the FDA's LDT rule provides temporary relief but regulatory uncertainty remains.

Next Steps

• Continue to build and publish clinical evidence-base to support testing services in key indications.
• Pursue reimbursement coverage from Medicare and other payors for additional diagnostic tests and indications.
• Further increase sales to existing biopharma customers and expand the customer base within each segment.
• Develop a growing set of state-of-the-art services and advance operational infrastructure.
• Leverage Tempus's sales force to grow the clinical diagnostic business, particularly for NeXT Personal Dx.
• Fulfill the new VA MVP task order received in August 2025 during the first three quarters of 2026.
• Invest in research and development to support clinical diagnostic offerings and technology development, including automation of laboratory processes.
• Increase capital expenditures to $8-10 million in 2026 and $10-12 million in 2027 and 2028 to expand NeXT Personal Dx capacity.
• Actively market the vacated Menlo Park facility for sublease.
• Monitor and comply with evolving data privacy and security obligations, including potential new AI regulations.

Key Dates

Recommendation

The company faces significant financial challenges, including an 18% revenue decline in 2025 and persistent net losses, exacerbated by the loss of a material commercial relationship with Natera. While the securing of Medicare coverage for NeXT Personal Dx in breast and lung cancer, coupled with increased clinical test volumes and expanded partnerships with Tempus and Merck, provides a strong foundation for future growth, the path to profitability remains uncertain. The company's reliance on a few key customers and suppliers, along with the need for further capital raises, presents notable risks. Given the mixed signals—strong product development and market access gains against a backdrop of financial losses and customer concentration shifts—a 'hold' recommendation is appropriate. Investors should monitor the execution of commercialization strategies, the impact of new Medicare coverage on revenue, and progress towards sustainable profitability.

Keywords

Cancer Genomic Testing, Precision Oncology, Personalized Cancer Therapies, Minimal Residual Disease (MRD), Liquid Biopsy, Next-Generation Sequencing (NGS), Clinical Diagnostics, Biomarker Discovery, Clinical Trials, Immuno-oncology, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Medicare Coverage, FDA Regulation, CLIA Certified, CAP Accredited, Tempus AI, Moderna, VA Million Veteran Program (VA MVP), Intellectual Property, Biopharmaceutical, Healthcare Technology